dusquetide
·Code: SGX945
dusquetide: developed by 1 company · 1 clinical trial tracked.
dusquetide evidence translation
What we can confirm
1 tracked trial
What it means
Source-backed records connect dusquetide to SNGX; that link alone does not prove the drug works.
What to watch
Watch trial status, endpoints, and the next source-backed update.
BioSniper AIPage evidence connected
Prepared research question
How could dusquetide → SNGX affect its developer, and what evidence supports the link?
Run cited research
Traceable citations · Unknowns marked
See linked entities and source evidence1 indications · 0 study sponsors
Related indications
Behçet Disease
Study sponsors
No additional listed-company sponsor is linked.
Development Pipeline (1)
| Company | Phase |
|---|---|
| SOLIGENIX, INC. (SNGX) Behçet Disease | Phase 2 |
Clinical Trials (1)
Pilot Study of SGX945 (Dusquetide) in the Treatment of Aphthous Ulcers in Behcet's Disease
Primary endpoint: Number of Oral Ulcers
Interventionalopen8 enrolledStarted 2024-11Completion 2025-061 site · Turkey (Türkiye)Soligenix
Frequently asked questions
Who is developing dusquetide?
dusquetide is being developed by SOLIGENIX, INC..
How many clinical trials involve dusquetide?
BioSniper tracks 1 clinical trial involving dusquetide.